Novo Nordisk dropped after management forecasts weaker 2026 growth, shifting attention from recent results to pricing pressure and rising competition in obesity treatments.
Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook
view original post